Case Report: Genetic profiling of small intestine metastasis from poorly differentiated non-small cell lung cancer: report of 2 cases and literature review of the past 5 years

Background: Poorly differentiated non-small cell lung cancer (NSCLC) is characteristic of high rate of distant metastasis and late stages at diagnosis. Small intestine metastasis is a rare but severe complication of lung cancer with a high rate of mortality. However, there is currently a lack of genetic profile studies on the small intestine metastasis of lung cancer.

Case presentations: We present 2 cases of male patients in their 60s with primary NSCLC of low differentiation, initially with no distant metastasis detected. Biopsy samples were obtained from the primary pulmonary lesions, and both patients received systematic radiotherapy (RT) and chemotherapy. However, both cases presented with abdominal pain and distension, and immunohistochemistry of small intestine biopsy samples obtained by endoscopy confirmed lung cancer metastasis. Next generation sequencing was used to explore the genetic profiles from the biopsy samples of both the primary pulmonary lesions and small intestine metastases. The correlated genes responsible for the small intestine metastasis from poorly differentiated NSCLC in these 2 patients included TP53, LRP1B, and FGFR2. The reports of small intestine metastasis from poorly differentiated NSCLC with the past 5 years were systematically reviewed and summarized subsequently.

Conclusions: Poorly differentiated NSCLC with small intestine metastases, while rare, substantially impacts the prognosis and poses major challenges for diagnosis and treatment. Through comparisons of genetic profiles between patients and in the same patient before and after metastasis, we identified the mutations in genes such as TP53, LRP1B, and FGFR2, which were correlated with the occurrence and progression of poorly differentiated NSCLC, as well as its small intestinal metastasis. This discovery has the potential to guide clinicians in developing personalized treatment plans through the manipulation of targeted and radiation therapies.

1 Introduction

Global cancer statistics revealed that lung cancer is the leading cause of cancer-related mortality worldwide (1). Non-small cell lung cancer (NSCLC) accounts for the majority (approximately 85%) of lung cancer cases. Compared with well differentiated ones, poorly differentiated NSCLC had an increased mortality by 83% and a 2.1-fold increase of recurrence due to its rapid growth rate and high metastasis propensity (2). More than 60% poorly differentiated NSCLC patients suffer from distant metastasis (3), including lymph nodes, liver, adrenal glands, bone, and brain. The occurrence of gastrointestinal tract metastasis is relatively uncommon, with only 1.77% reported, but it severely impacts the survival of lung cancer patients (4). A retrospective analysis of 366 lung cancer patients with gastrointestinal metastasis revealed that over half of them passed away within 3 months from diagnosis, with a median overall survival of 2.8 months (5). Among them, small intestine metastasis was further rare, reported in 11.9% of gastrointestinal cases, but substantially shortened the survival of lung cancer patients (6).

With technological development, next generation sequencing (NGS) is increasingly applied to detect genetic alterations and guide personalized treatments for patients in clinic. It has been demonstrated that mutations in driver genes such as EGFR, ALK, and KRAS are associated with metastases in various sites in NSCLC, including the brain, bone, liver, and lungs (7), but not the intestine. Reports and studies on lung cancer with small intestine metastasis remain relatively limited. Early detection or prediction is critical and necessary to improve efficacy and patient survival.

In this report, we presented 2 cases of poorly differentiated NSCLC with small intestine metastasis. By juxtaposing their NGS results, we unearthed the most correlated genes, including but not limited to, TP53, LRP1B, and FGFR2. Investigating genetic profiles in NSCLC with small intestine metastasis is crucial for early detection and prevention, and may provide insights to the underlying molecular mechanisms and potential therapeutic targets.

2 Case presentations

2.1 Case 1

The patient, a 61-year-old male, presented to the local hospital in April 2022 with complaints of dizziness and fatigue. A left upper lobe partial resection with lymph node clearance was performed after a 21 mm x 15 mm mass was found on a chest computed tomography (CT). Postoperative pathology revealed infiltrating adenocarcinoma with low to moderate differentiation. Immunohistochemistry revealed partial positive staining for CK7, focal positive staining for NapsinA, and TTF-1, negative staining for CK20. After thorough examination, the diagnosis of the malignant tumor in the left lung was confirmed as pT1cN0M0. Four cycles of PP regimen (Cisplatin + Pemetrexed) chemotherapy were given postoperatively, followed by radiotherapy (RT) of 56 GY/25 F from September 10 to November 14, 2022.

On January 6, 2023, the patient was admitted to our hospital due to abdominal pain and distension. CT examination of the abdomen and pelvis showed segmental thickening of the small intestinal wall in the right upper abdomen and multiple enlarged lymph nodes in the pelvic and inguinal regions (Figure 1A). On January 16, 2023, endoscopic examination of the small intestine revealed an ulcerated tumor in the jejunum, occupying approximately 2/3 of the lumen, located approximately 100 cm from the pylorus (Figure 1B). Histopathological examination of the biopsy specimen showed a high-grade cancer-like lesion in the submucosal layer of the small intestine. Immunohistochemistry demonstrated weakly positive expression of CK, positive expression of CK7 and Vimentin, negative expression of NapsinA, TTF-1, CK20. The diagnosis of undifferentiated cancer was considered.

FIGURE 1

Figure 1 Clinical and imaging features of the 2 cases. (A) Abdominal CT image of Patient 1. (B) Small intestine endoscopy image of Patient 1. (C) Flowchart of Patient 1’s diagnosis and treatment course. (D) Abdominal CT image of Patient 2. (E) Small bowel endoscopy image of Patient 2. (F) Flowchart of Patient 2’s diagnosis and treatment course.

From January 20 to May 19, 2023, the patient underwent 6 cycles of maintenance therapy with Tislelizumab. The therapeutic response was assessed every 2 cycles and classified as stable disease (SD) (Figure 1C).

2.2 Case 2

The patient, a 65-year-old man, was admitted to the hospital on April 6, 2021 due to a one-month history of coughing and phlegm. Chest CT scans revealed soft tissue nodules in the upper and middle lobes of the right lung, as well as soft tissue masses in the right pulmonary hilum and multiple enlarged lymph nodes in the mediastinum and right pulmonary hilum. No other malignant tumors or signs of metastasis were found in other parts of the body on PET/CT. A sample of the right lung mass and the 7th groups of lymph nodes were taken for pathological examination, which revealed poorly differentiated cancer. Immunohistochemistry showed positive expression of CK7, along with negative expression of TTF-1. The final diagnosis was low-grade lung cancer in the right lung, staging as T4N2MO. The patient had a smoking history of more than 40 years, averagely smoking 20 cigarettes per day.

From April 29 to June 18, 2021, the patient received 2 cycles chemotherapy of EP regimen (Etoposide + Nedaplatin) and chest RT with a total dose of 60 GY/30 F. On July 21, 2021, a review of the enhanced CT scan of the brain showed abnormal signals in the left temporal and parietal lobes, suggesting metastasis. Therefore, the patient received brain RT with a total dose of 30 GY/3 F, and the treatment plan was changed to chemotherapy of TP regimen (Albumin paclitaxel + Nedaplatin) combined with immunotherapy of Pembrolizumab for 4 cycles. The efficacy evaluation showed SD in the lungs and complete response (CR) in the brain. Starting from November 17, 2021, the patient received single-agent Pembrolizumab as maintenance for 19 cycles, and the efficacy evaluation showed SD.

On January 4, 2023, the patient returned for a abdominal CT due to hoarseness and abdominal distension, which showed multiple enlarged lymph nodes in the 2R region of the mediastinum, thickening of the wall of the jejunum in the upper left abdomen (Figure 1D). On January 13, 2023, a small intestine endoscopy revealed a luminal growth in the upper part of the jejunum, located approximately 35 cm from the pylorus (Figure 1E), and biopsy confirmed poorly differentiated cancer. Immunohistochemistry showed positive staining for CK7 and NapsinA, negative staining for TTF-1 and CK20. The possibility of poorly differentiated lung cancer with jejunal metastasis was considered.

From January 12, 2023, the patient received RT for swollen mediastinal lymph nodes in 2R region, administering a dose of 45 GY/15 F. Between February 8 and March 25, 2023, the patient underwent chemotherapy with Gemcitabine in combination with immunotherapy of Pembrolizumab for 3 cycles. Upon evaluation in April 2023, the therapeutic effect was classified as SD, which prompted a treatment regimen of immunotherapy maintenance with Pembrolizumab. The patient is currently receiving regular treatment (Figure 1F).

2.3 Genetic profiling of the 2 patients

We compiled the NGS results of both patients, including the lung tumor of patient 1 and the lung and small intestine masses of patient 2 (Figure 2A). In Patient 1, the top 5 genes with the highest mutation frequency were TP53, MGA, PBRM1, PIK3CG, and MET, whereas in Patient 2, they were TP53, ABCG2, LRP1B, FAT3, and PTPRS. Furthermore, we observed that both cases exhibited some shared genetic mutations, such as TP53 and LRP1B, while Patient 2 experienced a novel gene mutation, FGFR2, after small intestine metastasis (Figure 2B).

FIGURE 2

Figure 2 Molecular features of the 2 patients. (A) Mutation genes and their mutation frequencies. (B) Comparison of mutation sites and their mutation frequencies.

3 Discussion and literature review

Our analysis of reported cases small intestine metastasis from NSCLC over the past 5 years indicated that most patients were over 60 years old (Figure 3A), the primary pathological type was mostly adenocarcinoma (Figure 3B), and that the initial symptoms of metastatic disease typically manifested as abdominal pain and anemia, with a poor prognosis that often resulted in death within 6 months (Figure 3C, Table 1).

FIGURE 3

Figure 3 Clinical features of small Intestine metastasis from NSCLC reported in recent 5 years. (A) Age range. (B) Pathological types. (C) Survival curves made for integrating the prognosis.

TABLE 1

Table 1 Reported cases of small intestine metastasis from primary NSCLC within the past 5 years.

We discovered that the mutations in these two patients were predominantly missense mutations. TP53 is the most commonly mutated gene in human cancer, and 70% of its mutations are missense in the DNA-binding domain (29). These mutations increase the incidence of distant metastasis, and are associated with reduced survival rates. TP53 serves as the major prognostic factor for early and advanced NSCLC, with an OS of 27 vs. 19 months (p < 0.001) (30). The co-occurring mutations with other genes such as EGFR, STK11, or KRAS have been shown to be independent biomarkers for immune checkpoint inhibitors. LRP1B was reported to reduce NSCLC cell proliferation and migration as a putative tumor suppressor, and its loss-of-function mutations might lead to oncogenesis (31). Compared with the NGS results before small intestine metastasis in patient 2, a newly emerging mutation of FGFR2 was found in the metastatic tumors. A retrospective analysis of 5,557 Chinese solid tumor patients showed that the frequency of FGFR2 alterations in lung cancer was 1%, and FGFR2 was highly expressed in NSCLC tissues, which was correlated with tumor metastasis and poor prognosis (32). Targeted therapy against FGFR2 has become a hot topic in lung cancer treatment, and the role of FGFR inhibitors including ponatinib, regorafenib, pazopanib, lenvatinib, and nintedanib in NSCLC is being intensively studied.

Between patients, there existed some distinct genetic subregions. The heterogeneity of either patient’s tumor might serve as one contributing factor, whereby diverse subclonal populations or mutational patterns might even coexist within a single patient’s sample. Tumor heterogeneity engenders high genetic, epigenetic, and phenotypic diversity among tumor cells, thus constituting a significant constraint on targeted therapies (33). In addition, tumor progression and evolution epitomize a dynamic process, wherein the course may vary among different patients, owing to disparities such as the tumor microenvironment. One aspect we can ascertain is that investigating shared mutated genes holds promise as a future avenue of researches.

Furthermore, the gene mutations in the primary lung tumors were essentially the same as those in the metastatic tumors. However, the mutation frequency decreased after the small intestine metastasis, leading us to speculate that the metastasis might cause selective pressure on the NSCLC cells, resulting in the survival and expansion of a specific subset of cells with lower mutation frequency. Only 20% of detected mutations were demonstrated to exhibit significant alterations following conventional therapy, including a tendency towards a decrease in mutation frequency.

NGS was not conducted on the small intestine metastasis in Patient 1 due to the inherently limited quantity of the endoscopically obtained tissue sample. The sample was utilized not only to ascertain the origin of the small intestine mass whether primary or metastatic, but also underwent additional immunohistochemical analyses. Subsequently, PD-L1 testing was performed to further establish immunotherapy indications. Determining the nature of the tumor and guiding immunotherapy decisions stand as paramount considerations for clinical practitioners. Furthermore, the incomparability of the patient’s blood sample results led us to abandon the notion of utilizing blood samples.

The treatment of intestine metastasis of lung cancer is not standardized in clinical practice. For patients with multiple metastases of lung cancer, RT and chemotherapy are preferred, and surgery can be an effective palliative treatment for severe complications such as bleeding, obstruction, and perforation. RT can reduce the risk of distant metastasis in early-stage NSCLC patients. In NSCLC cases with small intestine metastasis, RT can further control the growth of metastatic lesions and alleviate abdominal pain and digestive dysfunction. The efficacy of RT is influenced by genomic molecular variations that determine the radiosensitivity of cancer cells. Moreover, RT can enhance the efficacy of systemic treatments through its abscopal effects. In cases of metastatic lung cancer, concurrent local RT and metastatic targeting therapy can strengthen the sustained control of local metastases (34). Further research is needed to determine the optimal combination and sequence of RT and other treatments, such as chemotherapy or targeted therapy.

More molecular studies are required to elucidate the underlying mechanisms driving NSCLC migration to the small intestine. The mutated genes TP53 and LRP1B, shared by the 2 patients, along with the newly mutated gene FGFR2 that has emerged after small bowel metastasis, need to be further verified as the driving force behind the spread of lung cancer to the small intestine. Targeting the mutated genes or their downstream signaling pathways represents a breakthrough for exploring novel therapeutic strategies.

4 Conclusions

Metastasis is a complex multi-step process that involves various factors such as tumor microenvironment, genetic instability, and immune response. It is essential to perform molecular marker detection in NSCLC patients and clarify the correlation between the pattern of small intestine metastasis and driver gene mutations. This not only enables the identification of tumor progression, but also serves as a biological predictor of radiation sensitivity and an identifying factor for potential therapeutic targets, thereby guiding personalized treatment plans.

5 Patient’s perspective and informed consent

The emergence of small bowel metastasis signified disease progression for the patient. The patient exhibited high compliance during further examinations and treatments, and demonstrated an understanding of the importance of NGS testing. In the absence of therapeutic targets, the patient received immunotherapy. The efficacy assessments after every two cycles showed stable disease, with an improvement in the patient’s quality of life.

The patient in this case report had given consent for anonymous publication.

Data availability statement

The datasets presented in this article are not readily available because of ethical/privacy restrictions. Requests to access the datasets should be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by Zhongnan Hospital of Wuhan University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

YG: Project administration, Supervision, Writing – review & editing. MW: Visualization, Writing – original draft. GC: Data curation, Writing – original draft. JL: Investigation, Writing – original draft. ZF: Investigation, Writing – original draft. YL: Investigation, Writing – original draft. CX: Project administration, Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by National Natural Science Foundation of China (81800429 and 81972852), Young and Middle-Aged Medical Backbone Talents of Wuhan (WHQG201902), Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University (ZNJC202007), Medical Science and Technology Innovation Platform Construction, Support Project of Zhongnan Hospital of Wuhan University (PTXM2022009), and Chinese Society of Clinical Oncology TopAlliance Tumor Immune Research Fund (Y-JS2019-036).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg (2006) 131(5):1014–20. doi: 10.1016/j.jtcvs.2005.12.057

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, et al. et al: Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer (2022) 21(1):25. doi: 10.1186/s12943-021-01462-z

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Yang CJ, Hwang JJ, Kang WY, Chong IW, Wang TH, Sheu CC, et al. Gastro-intestinal metastasis of primary lung carcinoma: clinical presentations and outcome. Lung Cancer (Amsterdam Netherlands) (2006) 54(3):319–23. doi: 10.1016/j.lungcan.2006.08.007

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Hu Y, Feit N, Huang Y, Xu W, Zheng S, Li X. Gastrointestinal metastasis of primary lung cancer: An analysis of 366 cases. Oncol Lett (2018) 15(6):9766–76. doi: 10.3892/ol.2018.8575

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Yoshimoto A, Kasahara K, Kawashima A. Gastrointestinal metastases from primary lung cancer. Eur J Cancer (Oxford Engl 1990) (2006) 42(18):3157–60. doi: 10.1016/j.ejca.2006.08.030

CrossRef Full Text | Google Scholar

7. Gao G, Deng L. [Association between EGFR, ALK and KRAS gene status and synchronous distant Organ metastasis in non-small cell lung cancer]. Zhongguo fei ai za zhi = Chin J Lung Cancer (2018) 21(7):536–42. doi: 10.3779/j.issn.1009-3419.2018.07.06

CrossRef Full Text | Google Scholar

8. Ogasawara N, Ono S, Sugiyama T, Adachi K, Yamaguchi Y, Izawa S, et al. Small-intestinal metastasis from lung carcinoma. Case Rep Gastroenterol (2022) 16(1):195–200. doi: 10.1159/000523663

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Saldaña-Dueñas C, Rullán-Iriarte M, Macías-Mendizábal E. Anemia como presentación inicial del cáncer de pulmón con afectación intestinal metastásica. Rev Gastroenterología México (2019) 84(2):259–62. doi: 10.1016/j.rgmx.2018.04.003

CrossRef Full Text | Google Scholar

10. Kosciuszek ND, Noel P, Takabe K, Seitelman E, Datta R, Gunasekaran G, et al. Intraluminal small bowel metastasis from primary lung cancer. World J Oncol (2022) 13(6):409–16. doi: 10.14740/wjon1532

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Li X, Li S, Ma Z, Zhao S, Wang X, Wen D. Multiple gastrointestinal metastases of squamous-cell lung cancer: A case report. Medicine (2018) 97(24):e11027. doi: 10.1097/MD.0000000000011027

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Wang J, Chen Y, Zhang S, Chen Q. Perforation of small intestine secondary to metastatic lung adenocarcinoma: A case report. Medicine (2018) 97(49):e13469. doi: 10.1097/MD.0000000000013469

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Kosasih S, Muhammad Nawawi KN, Wong Z, Chia Hsin DC, Ban AY, Raja Ali RA. Upper gastrointestinal bleed due to duodenal metastases of lung adenocarcinoma: Report of two cases and review of literature. Case Rep Med (2019) 2019:3437056. doi: 10.1155/2019/3437056

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Misiakos EP, Gouloumi AR, Schizas D, Damaskou V, Tsapralis D, Farrugia FA, et al. Small bowel perforation with multiple intestinal metastases from lung carcinoma: A case report. Oncol Lett (2019) 17(4):3862–6. doi: 10.3892/ol.2019.10031

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Zhu M, Shu J, Liu X, Leng L, Wen Q. Gastrointestinal hemorrhage caused by duodenal metastasis from a primary lung adenocarcinoma: A case report. Mol Clin Oncol (2021) 14(3):62. doi: 10.3892/mco.2021.2224

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Sautto F, Tinsley S, Neychev V. Small bowel perforation due to rare metastasis from stage IV lung adenocarcinoma. Cureus (2022) 14(9):e29551. doi: 10.7759/cureus.29551

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Kim MC, Jang MH, Ahn JH. Metastatic large cell carcinoma of the lung: A rare cause of acute small bowel obstruction. Thorac Cancer (2020) 11(11):3379–82. doi: 10.1111/1759-7714.13656

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Zhu F, Lin J, Liao H, Wang Y, Pan J. Gene profiling of metastatic small intestinal squamous cell carcinoma after lung squamous cell carcinoma surgery: a case report. Trans Cancer Res (2022) 11(4):967–72. doi: 10.21037/tcr-22-481

CrossRef Full Text | Google Scholar

19. Suzuki T, Noda M, Yamamura A, Ohishi H, Notsuda H, Eba S, et al. Persistent fecal occult blood due to the small intestinal metastasis of pleomorphic lung carcinoma. J Surg Case Rep (2022) 2022(2):rjac043. doi: 10.1093/jscr/rjac043

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Rejab H, Fendri S, Trigui A, Abid B, Youssef M, Ketata S, et al. A rare case of small intestinal metastasis from lung cancer. Clin Case Rep (2022) 10(11):e6666. doi: 10.1002/ccr3.6666

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Chen HF, Zhang QX, Zhu YC, Du KQ, Li XF, Wu LX, et al. Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib. OncoTargets Ther (2018) 11:7821–5. doi: 10.2147/OTT.S178985

CrossRef Full Text | Google Scholar

22. Ohira T, Iraha A, Kinjo T, Hokama A, Fujita J. Small intestinal metastasis from primary lung cancer. Polish Arch Internal Med (2019) 129(1):57–8. doi: 10.20452/pamw.4374

CrossRef Full Text | Google Scholar

23. Pierro A, Cilla S, De Ninno M, Sallustio G. Recurrent jejunal metastasis from occult lung cancer. Digestive liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver (2019) 51(1):166. doi: 10.1016/j.dld.2018.07.008

CrossRef Full Text | Google Scholar

24. Nguyen BD, Ryan MS. Gastrointestinal: Positron emission tomography–computed tomography imaging of multifocal intestinal metastasis from primary lung cancer. J Gastroenterol Hepatol (2019) 34(5):814–4. doi: 10.1111/jgh.14591

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Eto R, Hoshino I, Takiguchi N, Tonooka T, Gunji H, Kuwayama N, et al. Surgical resection of undifferentiated pleomorphic sarcoma (UPS) with jejunal perforation, a suspected case of metastasis of lung cancer. Clin J Gastroenterol (2021) 14(5):1386–91. doi: 10.1007/s12328-021-01483-7

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Xie X, Tu N, Wang Q, Cheng Z, Han X, Bu L. (18) F-FDG PET/CT imaging of small intestinal metastasis from pulmonary sarcomatoid carcinoma: brief report and review of the literature. Thorac Cancer (2020) 11(8):2325–30. doi: 10.1111/1759-7714.13468

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Gao C, Zou Q, Liu H. Pulmonary sarcomatoid carcinoma with epiglottis and ileum metastasis detected by 18F-FDG PET/CT. Clin Nucl Med (2022) 47(3):231–3. doi: 10.1097/RLU.0000000000003936

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Pleština S, Librenjak N, Marušić A, Batelja Vuletić L, Janevski Z, Jakopović M. An extremely rare primary sarcoma of the lung with peritoneal and small bowel metastases: a case report. World J Surg Oncol (2019) 17(1):147. doi: 10.1186/s12957-019-1691-8

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Sabapathy K, Lane DP. Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol (2018) 15(1):13–30. doi: 10.1038/nrclinonc.2017.151

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Jiao XD, Qin BD, You P, Cai J, Zang YS. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer (Amsterdam Netherlands) (2018) 123:70–5. doi: 10.1016/j.lungcan.2018.07.003

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Li Y, Knisely JM, Lu W, McCormick LM, Wang J, Henkin J, et al. Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. J Biol Chem (2002) 277(44):42366–71. doi: 10.1074/jbc.M207705200

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Gu W, Yang J, Wang Y, Xu J, Wang X, Du F, et al. Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing. Am J Cancer Res (2021) 11(8):3893–906.

PubMed Abstract | Google Scholar

33. Maleki EH, Bahrami AR, Matin MM. Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. Genes Dis (2024) 11(1):189–204. doi: 10.1016/j.gendis.2022.11.025

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol (2023) 24(3):e121–32. doi: 10.1016/S1470-2045(22)00752-5

PubMed Abstract | CrossRef Full Text | Google Scholar